Morbid Obesity
Conditions
Keywords
Liraglutide, Morbid obesity, secondary bariatric surgery, revisional bariatric surgery
Brief summary
Our primary objective is to assess the effect of Liraglutide on weight loss in patients who have undergone secondary bariatric surgeries. We set out to assess if Liraglutide is a viable option to augment weight loss in said category.
Interventions
Subcutaneous injection of GLP-1 agonist
Sponsors
General Committee of Teaching Hospitals and Institutes, Egypt
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Undergone primary bariatric surgery * Need secondary bariatric surgery due to either weight regain (regained weight to have BMI \> 35) or medical associated diseases
Exclusion criteria
* Prior use of GLP-1 agonist * Past history of pancreatitis * Personal or family history of medullary thyroid cancer * Pregnancy or lactation * Acute coronary syndrome * Hepatic or renal dysfunction * Active malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage Total weight loss | 6 months |
| Percentage Excess body weight loss | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| BMI | 6 months |
| HbA1C | 6 months |
| Fasting Blood Glucose (FBG) | 6 months |
| HOMA-IR | 6 months |
| Comorbidities | 6 months |
| Blood pressure | 6 months |
| Lipid profile | 6 months |
| Sleep apnea | 6 months |
| Resolution of type 2 Diabetes Mellitus | 6 months |
| Weight | 6 months |
Countries
Egypt
Contacts
Primary ContactMohamed Ashour, PhD
Outcome results
None listed